Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation.

Autor: Bekadja MA; EHU 1st November, Oran, Algeria., Niederwiser D; Division of Hematology and Medical Oncology, University of Leipzig, Leipzig, Germany., Kharfan-Dabaja MA; Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA. KharfanDabaja.Mohamed@mayo.edu., El Fakih R; Adult Hematology, Stem Cell Transplant & Cellular Therapy, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. relfakih1@kfshrc.edu.sa., Garderet L; Centre de Recherche Saint-Antoine, Sorbonne Université-INSERM, UMR_S 938, Paris, France., Yakoub-Agha I; Centre Hospitalier Universitaire de Lille, Université de Lille, Lille, France., Greinix H; Division of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria., Weisdorf DJ; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA., Galeano S; Department of Hematology, Hospital Británico, Montevideo, Uruguay., Ahmed SO; Adult Hematology, Stem Cell Transplant & Cellular Therapy, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia., Chabanon C; Institut Paoli-Calmettes, Inserm CBT-1409 & Aix-Marseille Université, Marseille, France., Hashmi SK; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.; Department of Medicine, Sheikh Shakbout Medical City, Abu Dhabi, UAE.; College of Medicine & Health Sciences, Khalifa University, Abu Dhabi, UAE., Ruggeri A; San Raffaele Scientific Institute, Milano, Italy., Gergis U; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA., Bazarbachi A; Blood and Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon., Hamad N; Australia and New Zealand Transplant and Cellular Therapies (ANZTCT), Department of Haematology, St Vincent's Hospital Sydney, Sydney, NSW, Australia.; School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.; School of Medicine, Sydney University of Notre Dame, Notre Dame, WS, Australia., Albeihany A; King Faisal Specialist Hospital and Research Center, Madinah, Saudi Arabia., Pasquini M; Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA., Hanbali A; Adult Hematology, Stem Cell Transplant & Cellular Therapy, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia., Szer J; Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital Melbourne, Melbourne, VIC, Australia., Kodera Y; Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University School of Medicine, Nagakute, Japan., Kumar A; Department of Internal Medicine Director, Research Methodology and Biostatistics Core, Office of Research Morsani College of Medicine, University of South Florida, Tampa, FL, USA., Elhassan T; Adult Hematology, Stem Cell Transplant & Cellular Therapy, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia., McLornan D; Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK., Worel N; Department of Transfusion Medicine and Cell Therapy, Medical University of Vienna, Vienna, Austria., Greco R; Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milano, Italy., Mohty M; Centre de Recherche Saint-Antoine, Sorbonne Université-INSERM, UMR_S 938, Paris, France., Atsuta Y; Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.; Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan., Koh M; St. George's Hospital and Medical School, London, UK.; Cell Therapy Facility, Blood Services Group, Health Sciences Authority, Singapore, Singapore., Sureda A; Hematology Department, Institut Català d'Oncologia-Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain., Rondelli D; Division of Hematology/Oncology, University of Illinois at Chicago, Chicago, IL, USA., Aljurf M; Adult Hematology, Stem Cell Transplant & Cellular Therapy, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. maljurf@kfshrc.edu.sa., Rasheed W; Adult Hematology, Stem Cell Transplant & Cellular Therapy, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Jazyk: angličtina
Zdroj: Bone marrow transplantation [Bone Marrow Transplant] 2024 Oct 07. Date of Electronic Publication: 2024 Oct 07.
DOI: 10.1038/s41409-024-02431-y
Abstrakt: Autologous peripheral blood stem cell (PBSC) transplantation is a standard treatment of multiple myeloma (MM), Hodgkin lymphoma and various subtypes of non-Hodgkin lymphoma. Cryopreservation of hematopoietic stem cells is standard practice that allows time for delivery of conditioning regimen prior to cell infusion. The aim of this Worldwide Network for Blood & Marrow Transplantation (WBMT) work was to assess existing evidence on non-cryopreserved autologous transplants through a systematic review/meta-analysis, to study feasibility and safety of this approach. We searched PubMed, Web of Science and SCOPUS for studies that utilized non-cryopreserved autologous PBSC transplantation. Identified literature was reviewed for information on mobilization, apheresis, preservation and viability, conditioning regimen, engraftment, response, and survival. Results highlight collective experience from 19 transplant centers (1686 patients), that performed autologous transplants using non-cryopreserved PBSCs. The mean of infused CD34+ was 5.6 × 10 6 /kg. Stem cell viability at transplantation was >90% in MM and >75% in lymphomas, after a storage time of 24-144 h at +4 °C. Mean time-to-neutrophil engraftment was 12 days and 15.3 days for platelets. Pooled proportion estimates of day 100 transplant-related mortality and graft failure were 1% and 0%, respectively. Non-cryopreservation of apheresed autologous PBSCs appears feasible and safe.
(© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: